Your browser doesn't support javascript.
loading
von Willebrand factor antigen levels in plasma of patients with malignant breast disease
Röhsig, L. M; Damin, D. C; Stefani, S. D; Castro Júnior, C. G; Roisenberg, I; Schwartsmann, G.
  • Röhsig, L. M; Universidade Federal do Rio Grande do Sul. Hospital de Clínicas de Porto Alegre. Unidade de Oncologia Médica. Porto Alegre. BR
  • Damin, D. C; Universidade Federal do Rio Grande do Sul. Hospital de Clínicas de Porto Alegre. Unidade de Oncologia Médica. Porto Alegre. BR
  • Stefani, S. D; Universidade Federal do Rio Grande do Sul. Hospital de Clínicas de Porto Alegre. Unidade de Oncologia Médica. Porto Alegre. BR
  • Castro Júnior, C. G; Universidade Federal do Rio Grande do Sul. Hospital de Clínicas de Porto Alegre. Unidade de Oncologia Médica. Porto Alegre. BR
  • Roisenberg, I; Universidade Federal do Rio Grande do Sul. Departamento de Genética. Porto Alegre. BR
  • Schwartsmann, G; Universidade Federal do Rio Grande do Sul. Hospital de Clínicas de Porto Alegre. Unidade de Oncologia Médica. Porto Alegre. BR
Braz. j. med. biol. res ; 34(9): 1125-1129, Sept. 2001. tab
Article in English | LILACS | ID: lil-290408
RESUMO
von Willebrand factor (vWF) is a protein that mediates platelet adherence to the subendothelium during primary hemostasis. High plasma vWF concentrations have been reported in patients with various types of cancer, such as head and neck, laryngeal and prostatic cancer, probably representing an acute phase reactant. In the present study we determined the plasma levels of vWF antigen (vWFAg) by quantitative immunoelectrophoresis in 128 female patients with breast cancer as well as in 47 women with benign breast disease and in 27 healthy female controls. The levels of vWFAg were 170.7 + or - 78 U/dl in patients with cancer, 148.4 + or - 59 U/dl in patients with benign disease and 130.6 + or - 45 U/dl in controls (P<0.005). We also detected a significant increase in the levels of vWFAg (P<0.0001) in patients with advanced stages of the disease (stage IV = 263.3 + or - 113 U/dl, stage IIIB = 194.0 + or - 44 U/dl) as compared to those with earlier stages of the disease (stage I = 155.3 + or - 65 U/dl, stage IIA = 146.9 + or - 75 U/dl). In conclusion, vWF levels were increased in plasma of patients with malignant breast disease, and these levels correlated with tumor progression
Subject(s)
Full text: Available Index: LILACS (Americas) Main subject: Breast Neoplasms / Von Willebrand Factor / Antigens Type of study: Prognostic study Limits: Adolescent / Adult / Female / Humans Language: English Journal: Braz. j. med. biol. res Journal subject: Biology / Medicine Year: 2001 Type: Article Affiliation country: Brazil Institution/Affiliation country: Universidade Federal do Rio Grande do Sul/BR

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Breast Neoplasms / Von Willebrand Factor / Antigens Type of study: Prognostic study Limits: Adolescent / Adult / Female / Humans Language: English Journal: Braz. j. med. biol. res Journal subject: Biology / Medicine Year: 2001 Type: Article Affiliation country: Brazil Institution/Affiliation country: Universidade Federal do Rio Grande do Sul/BR